Tango Therapeutics Inc. (TNGX)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Tango Therapeutics as Graham would: first ask whether the business has durable earning power, then whether the price offers a margin of safety. Tango is a precision-oncology company with early-stage PRMT5 and other programs. The science may be promising, but the financial record shows no consistent profits. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $55.3 million and diluted EPS of -$0.37. Fiscal Q1 2026, the quarter ended 2026-03-31, showed a net loss of $45.5 million and diluted EPS of -$0.32. One quarter did look different: fiscal Q3 2025, the quarter ended 2025-09-30, had revenue of $53.8 million, net income of $15.9 million, and diluted EPS of $0.13. But that was not repeated in the annual figures: FY2025, the year ended 2025-12-31, had revenue of $62.4 million but a net loss of $101.6 million; FY2024 had revenue of $42.1 million and a net loss of $130.3 million; FY2023 had revenue of $36.5 million and a net loss of $101.7 million. So revenue has grown, yet losses remain large. The balance sheet shows low leverage—D/E 0.03—and FairStock's Altman Z-Score of 45.86, but trailing free cash flow is -$144.3 million, a -3.9% FCF yield. At the 2026-10-13 close of $22.22, FairStock calculations show P/E -26.45 and P/B 8.17; the FairStock Score is 19/100. The moat is unproven; value depends on clinical data. I see no margin of safety in today's price for a cash-burning, pre-profit biotech.

In plain English: Tango Therapeutics is a small healthcare company working on new cancer drugs. It does not make steady profits, it has lost money in most recent periods, and it spends more cash than it brings in, although it has very little debt. At $22.22, the stock looks expensive compared with its assets and losses, so its value depends on whether its drug trials succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer